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Objectives: Whilst there are theoretical beneﬁts from pre-operatively draining the biliary tree prior to
pancreatoduodenectomy (PD), the current literature does not support this intervention. The aim of this
study was to explore the relationship between pre-operative stenting, bactibilia and outcome in a large
United Kingdom tertiary referral practice.
Methods: Patients undergoing PDwere identiﬁed from a prospectivelymaintained database. The presence
or absence of a stent prior to PD, and the results of bile cultures taken at PDwere related to the subsequent
post-operative course and the development of complications.
Results: 280 patients underwent PD for periampullary malignancies, all of whom presented with jaun-
dice. 118 patients were stented prior to referral (98 ERCP, 20 PTC). Bile cultures were positive more
frequently in the stent group (83% vs. 55%; p ¼ 0.000002) and bactibilia was more common after ERCP
than PTC (83% vs. 56%; p ¼ 0.006). The overall prevalence of complications was 54% in the stented and
41% in the non-stented group (p ¼ 0.03) with statistical signiﬁcance achieved for pancreatic leak
(p ¼ 0.013) and haemorrhagic complications (p ¼ 0.03). Comparing stent with no stent, there as no
difference in the 30-day mortalities (8.5% vs. 6.8%; p ¼ 0.6) or the 1-year mortality rates (35% vs. 28%;
p ¼ 0.21). Mortality rates in the infection versus no infection groups were comparable at 30 days (8.5% vs.
5.5%; p ¼ 0.21), and at 1 year (30.7% vs. 26.4%; p ¼ 0.25).
Conclusions: Pre-operative stent insertion prior to PD is associated with increased morbidity but not
mortality and this is greatest for stents placed at ERCP.
 2010 Published by Elsevier Ltd on behalf of Surgical Associates Ltd.1. Introduction
There is considerable debate as to the management of the
jaundiced patient with a pancreatic adenocarcinoma who is
a candidate for pancreatoduodenectomy (PD). There is experi-
mental evidence that biliary drainage improves nutritional status,
reduces the risk of endotoxaemia, and may improve immune
function1,2,3, although this has yet to be extrapolated to the clinical
setting. There is in addition literature demonstrating that jaundice
increases the prevalence of post-operative complications such as:
anastomotic leak rates; secondary haemorrhage; and post-opera-
tive renal failure4 and as such pancreatic resection should be
avoided until adequate decompression is achieved.5 There is also
recent evidence from a clinical study that despite the impaired
synthesis of vitamin k dependent clotting factors in patients withx: þ44 0121 4141833.
za).
Elsevier Ltd on behalf of Surgical Abiliary obstruction, jaundice is associated with a pro-coagulant
state which is reversed by stenting.6 Indeed, in his original
description, Whipple described his operation as a 2-stage proce-
dure speciﬁcally for this purpose.7
However, the potential beneﬁts of decompression through
stenting of the biliary tree have to be balanced by the morbidity
associated with the procedure and effects that stenting may have
on subsequent resection. There is no doubt that stenting in the
presence of jaundice is associated with a signiﬁcant morbidity,
some of the more important complications being: haemorrhage;
pancreatitis; and stent occlusion8 which occur in up to 50% of cases
as a result of the development of a bioﬁlm9 leading to recurrent
jaundice and subsequent cholangitis. One other important statistic
that is not evident from the literature is the number of patients who
are stented in the presence of a resectable tumour but suffer
signiﬁcant morbidity and are then deemed no longer suitable
candidates for surgery.
Contemporary data from renowned pancreatic institutions have
published large cohort studies all of which suggest that stenting isssociates Ltd.
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associated with increased morbidity, and in some cases mortality.
Surprisingly, there are only 2 adequately powered randomised
trials comparing internal biliary drainage followed by surgery with
surgery alone.17,18 In the more recent of the trials, van der Gaag and
colleagues studied 202 patients, 96 of whom were randomised to
surgery and 106 to stenting prior to surgery.18 They found the
overall complication rates to be 39% in the former and 74% in the
later group with morbidity attributed to stenting in 37% and to
the resection in 47%. Furthermore, three meta-analyses have
recently been published all of which concluded that pre-operative
biliary drainage offers no beneﬁt and as such should not be per-
formed routinely.14,19,20
The aim of this study was to assess the morbidity and mortality
associated with biliary stenting in a population of patients with
malignant periampullary cancers referred to a specialist pancreatic
tertiary referral centre.
2. Patients and methods
Consecutive patients undergoing PD for malignant disease were
identiﬁed from a prospectively maintained departmental database.
Patients undergoing resection of benign disease and malignant
disease affecting the body and tail of the pancreas were excluded.
Data were reviewed to identify those stented and those in which
a stent was not placed prior to PD.
For patients stented prior to PD, the type of proceduree internal
drainage via endoscopic retrograde cholangio pancreatography
(ERCP) or external drainage bymeans of percutaneous transhepatic
cholangiography (PTC) was noted as was the interval between
stenting and surgery. All stents used were polyethylene and were
either size 10 or 12 French.
The effectiveness of the stenting procedure in relieving biliary
obstruction was assessed through estimation of pre-operative
bilirubin and alkaline phosphatase levels. And pre-operative white
cell count was assessed as a marker of infection.
Antibiotic prophylaxis consisting of a second generation ceph-
alosporin and metronidazole were administered on induction of
anaesthesia and were continued for 2 doses post-operatively.
All patients had cultures taken directly from the bile at the time
of surgery, and where present, the proximal ends of biliary stents
were also cultured. Adjustments to antibiotic therapy weremade in
accordance with culture results.
Post-operative complicationswere documented including: biliary
and pancreatic leaks; septicaemia; gastrointestinal or intra-perito-
neal haemorrhage; cardiac arrhythmia/acute coronary syndrome;
pneumonia/respiratory failure; renal failure; and death.
A bile leak was deﬁned as the presence of bile in the drain after
the second post-operative day whilst a pancreatic leak was deﬁned
as the presence of amylase rich ﬂuid (>5000 IU/L) in the drain after
post-operative day 5. Infectious complications were diagnosed on
the basis of localized or systemic symptoms and signs, and
conﬁrmed by culture, with radiological investigations where indi-
cated to localize the source. Haemorrhagic complications were
identiﬁed on the basis of haemodynamic instability, overt blood
loss or the requirement for transfusion with the source being
conﬁrmed by endoscopic or radiological means. Documentation of
cardiac and respiratory complications was based on clinical ﬁnd-
ings conﬁrmed by electrocardiography and radiology with addi-
tional biochemical and microbiological tests where appropriate.
Renal impairment was deﬁned on the basis of deterioration in
renal function with or without the requirement for renal support.
The mortality was taken to be a 30-day post-operative mortality
and in addition the number of patients surviving 1-year was also
documented.The subsequent post-operative courses and the development of
complications were related to the presence or absence of stents and
identiﬁcation of infected bile.
The results were expressed as median with ranges in paren-
theses, and in case of complications, number experiencing the
complicationwith percentages in parentheses. Analyses performed
included the prevalence of complications in: stent versus no stent;
infection versus no infection; and the varying combination of
infection  stent.
All statistical analyses were performed using the SPSS for
Windows version 14.0 (SPSS Inc, Chicago, Ill, USA), and statistical
signiﬁcance was taken at the 5% level.
3. Results
In the period covered by the study, 280 patients presenting with
jaundice underwent PD for malignancies obstructing the distal bile
duct all of which underwent surgery with curative intent. There
were 128 females and 152males and themedian agewas 65.6 years
(Range: 21.7e83.0 years).
The histological types of the obstructing malignant tumours in
order of frequency were: pancreatic adenocarcinoma (n ¼ 148);
ampullary carcinoma (n ¼ 77); cholangiocarcinoma (n ¼ 25);
duodenal adenocarcinoma (n ¼ 21); acinar cell carcinoma (n ¼ 3);
cystic carcinoma (n ¼ 2); adenosquamous carcinoma (n ¼ 1);
spindle cell carcinoma (n ¼ 1); pseudo-papillary cystic carcinoma
(n ¼ 1) and anaplastic carcinoma (n ¼ 1). There were more
duodenal tumours in the non-stented group 19 vs. 2 but all other
pathological types shared a comparable distribution. Two hundred
and ﬁfty nine were pylorus preserving pancreatoduodenectomies
(PPPD) and 21 were classical Whipple’s operations.
A stent had been placed in 118 patients prior to referral to the
unit of which, 98 were placed at ERCP and 20 at PTC. Despite
stenting, the percentage of patients with a normal bilirubin level or
alkaline phosphatase at the time of PDwere comparable for stented
and non-stented groups at (38.1% vs. 42%, p ¼ 0.46) and (1.7% vs.
3.4%, p ¼ 0.45) respectively. There was however a signiﬁcant
difference in the mean bilirubin (98 vs. 130 mmol/L; p ¼ 0.032) and
alkaline phosphatise (664 vs. 709 IU/L; p ¼ 0.046) in the stented
group when compared to the non-stented cohort. There was no
difference in the mean white cell count between patient groups at
(8.4  109 vs. 8.9  109; p ¼ 0.14).
The interval from referral to surgery in the surgery alone group
was a median of 5 days (Range: 2e13) and from stenting to surgery
was 23 days (Range: 8e43 days).
Pre-operative cultures of bile  biliary stents were positive
signiﬁcantlymore frequently in the stent group at 98/118 compared
with the no stent group 91/162 (83% vs. 56%; p ¼ 0.000002).
Furthermore, a positive culture was obtained signiﬁcantly more
frequently following stenting performed at ERCP than PTC (83% vs.
55%; p ¼ 0.006). In the ERCP group, 33 of 81 cases of infected bile
grew a single organism and in the remainder cultures were poly-
microbial whilst in the PTC group, 64% of cultures were mono-
microbial and 36% grew multiple organisms (p ¼ 0.15).
The organisms identiﬁed from culture of the bile and stent tip
are summarised in Table 1. There were a wide variety of organisms
but no signiﬁcant differences were identiﬁed between the groups.
A growth of Candida species was the single most common isolate
being identiﬁed in 43/189 (22.8%) of patients with a positive
culture.
Complications for patients receiving a stent versus no stent are
summarised in Table 2. The overall prevalence of complications was
54% in the stented and 41% in the non-stented group (p¼ 0.03). The
prevalence of all complications except for cardiac were more
common in the cohort receiving a stent, with statistical signiﬁcance
Table 1
Organisms cultured from bile and/or stents of patients with and without stents
inserted prior to pancreatoduodenectomy.
Organism Stent No stent
Candida species 25 18
Enterococcus species 23 15
Mixed coliforms 16 19
Klebsiella species 19 10
Eschericha coli 16 6
Enterobacter species 12 7
Alpha-haemolytic Streptococci 5 6
Citrobacter species 6 2
Staphylococcus aures 4 1
Serratia species 4 1
Clostridium perfringens 3 1
Beta-haemolytic Streptococci 2 1
Bacteroides species 0 2
Staphylococcus epidermidis 1 1
Stenotrophomonas maltophilia 1 0
Lactobacillus species 1 0
Hafnia alvei 1 0
Pseudomonas species 1 0
Acinetobacter species 0 1
Table 3
Complication rates following pancreatoduodenectomy in relation to the presence or
absence of infection.
Complication Infection
(n ¼ 189)
No infection
(n ¼ 91)
Chi-square
(p value)
Pancreatic leak 31 (16.4%) 13 (14.3%) 0.21 (0.65)
Bile leak 6 (3.2%) 2 (2.2%) 0.24 (0.63)
Septicaeimia 22 (11.6%) 9 (9.9%) 0.19 (0.66)
Intra-abdominal
abscess
12 (6.3%) 8 (8.8%) 0.55 (0.46)
Gastrointestinal/
Intra-abdominal
haemorrhage
16 (8.5%) 8 (8.8%) 0.008 (0.9)
Wound infection/
dehiscence
35 (18.5%) 7 (7.7%) 5.6 (0.02)
Cardiac arrhythmia/
acute coronary
syndrome
22 (11.6%) 5 (5.5%) 2.66 (0.1)
Pneumonia/respiratory
failure
19 (10.1%) 10 (11%) 0.06 (0.81)
Renal Failure 11 (5.8%) 7 (7.7%) 0.36 (0.55)
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complications (p¼ 0.03). An analysis of presence of infection versus
no infection (Table 3.) revealed the prevalence of wound compli-
cations as the only signiﬁcant difference, with signiﬁcantly more
wound infections in those with infected bile.
Further analysis incorporating stents and infections into 4
groups namely: infection and stent; infection but no stent; stent
but no infection; and no stent or infection (Table 4) revealed no
signiﬁcant differences between any of the groups for any of the
complications.
In 68% of cases in which a post-operative infective complication
occurred, the causative organism was the same as identiﬁed from
the peri-operative bile culture.
Therewere no differences in the 30-daymortality at 8.5% vs. 6.8%
(p ¼ 0.6) or the 1-year mortality at 35% vs. 28% (p ¼ 0.21) when
comparing stent tonostent insertion. Furthermore,mortality rates in
the infection versus no infection groups were comparable at 30 days
at 8.5% vs. 5.5% (p¼ 0.21), and at 1 year at 30.7% vs. 26.4% (p¼ 0.25).4. Discussion
The primary ﬁnding of the study was that pre-operative biliary
stentingwas not beneﬁcial in terms of eithermorbidity ormortalityTable 2
Comparison of complication rates in patients with and without stents present at
time of pancreatoduodenectomy.
Complication Stent
(n ¼ 118)
No stent
(n ¼ 162)
Chi-square
(p value)
Pancreatic leak 26 (22%) 18 (11.1%) 6.15 (0.013)
Bile leak 4 (3.4%) 4 (2.5%) 0.21 (0.65)
Septicaeimia 16 (13.6%) 15 (9.3%) 1.28 (0.25)
Intra-abdominal
abscess
10 (8.5%) 10 (6.2%) 0.55 (0.46)
Gastrointestinal/
Intra-abdominal
haemorrhage
15 (12.7%) 9 (5.6%) 4.46 (0.03)
Wound infection/
dehiscence
22 (18.6%) 20 (12.3%) 2.12 (0.15)
Cardiac arrhythmia/
acute coronary
syndrome
9 (7.6%) 18 (11.1%) 0.95 (0.33)
Pneumonia/
respiratory failure
15 (12.7%) 14 (8.6%) 1.2 (0.27)
Renal Failure 11 (9.3%) 7 (4.3%) 2.8 (0.08)for patients undergoing PD, and indeed was associated with
increased risk for pancreatic leak as well as gastrointestinal and
intra-peritoneal bleeding. These ﬁgures are in keeping with the
published body of evidence that has found no beneﬁt to pre-oper-
ative stenting 1020. Proponents of stenting may argue that the lack
of a detrimental effect from stenting was a good thing however,
contrary to this is the argument that if a procedure with a recog-
nised side-effect proﬁle is to be performed then there needs to be
evidence of a beneﬁcial outcome. In this study, the prevalence of
infection was greater in the stented group and the patients being
stented suffered more pancreatic leaks and haemorrhagic compli-
cations than the non-stented patients. We would therefore be
against routine stenting.
There was no difference in the rates of infective complica-
tions between the stent and no stent groups. This is under-
standable as the source of the infection was the bile itself. In all
cases the bile duct is clipped following division to prevent bile
leakage into the peritoneal cavity during the reconstruction. As
a result of this manoeuvre, there is less opportunity for bacterial
contamination of the retroperitoneum or abdominal wall and
hence of infection.
One aspect that cannot be fully assessed in a study as such this is
the full extent of the morbidity and mortality from stenting. ERCP
and stenting, the more common means of drainage, is associated
with a morbidity of 1e25% including: bleeding; pancreatitis;
cholangitis; and perforation; together with a mortality of 0.2e1%
and a failure rate of 3e30%23 and it may be that some potentially
resectable patients may not have been resected as a result of
suffering these complications.
Despite the bilirubin being lower in the stented group, the
majority of patients did not have normal bilirubin or alkaline
phosphatise levels indicating that the stents were not draining
adequately. This may be related to delays between presentation and
surgery, however this was only a median of 23 days for the patients
undergoing stenting, and literature would suggest that plastic
stents should remain patent for between a median of 62e165
days.24 Another possibility, often overlooked, may be the formation
of delta-bilirubin, as the binding of bilirubin to plasma proteins
such as albumin prolongs its half life and delays the resolution of
jaundice.25 The percentage of delta-bilirubin increases with the
duration of jaundice. A further option is that the clinical histories
prior to presentation, diagnosis and referral may have been
signiﬁcantly longer than indicated in the case notes but this is
impossible to conﬁrm in a retrospective study.
Table 4
Combined effects of stenting and biliary infection on complication rates following pancreatoduodenectomy.
Complication Stent -ve
infection -ve
(n ¼ 71)
Stent þ ve
infection -ve
(n ¼ 20)
Stent -ve
infection þ ve
(n ¼ 91)
Stent þ ve
infection þ ve
(n ¼ 98)
Chi-square
(p value)
Pancreatic
Leak
9 (12.7%) 4 (20%) 9 (9.9%) 2 (22.4%) 6.45 (0.99)
Bile leak 1 (1.%) 1 (5%) 3 (3.3%) 3 (3.1%) 0.95 (0.81)
Septicaeimia 6 (8.5%) 3 (15%) 9 (9.9%) 13 (13.3%) 1.42 (0.70)
Intra-abdominal
Abscess
4 (5.6%) 3 (15%) 6 (6.6%) 6 (6.1%) 2.36 (0.50)
Haemorrhage 5 (7%) 3 (15%) 4 (4.4%) 12 (12.2%) 5.0 (0.17)
Wound
Complications
5 (7%) 2 (10%) 16 (17.6%) 19 (19.4%) 5.87 (0.12)
Cardiac
Complications
5 (7%) 0 (0%) 13 (14.4%) 9 (9.2%) 4.96 (0.17)
Respiratory
Complications
7 (9.9%) 3 (15%) 7 (7.7%) 12 (12.2%) 1.56 (0.67)
Renal
Failure
4 (5.6%) 3 (15%) 3 (3.3%) 5 (5.1%) 4.45 (0.22)
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surgery, was seen more commonly in the stent group, however,
bacteria were cultured from the bile of 55% of patients without
a stent present. This is keeping with the observation that obstruc-
tive jaundice is a signiﬁcant risk factor for the development of
bactibilia and subsequent cholangitis.26 Stenting further increases
this risk27 by providing an environment for the development of
a bacterial bioﬁlm.9
The same organisms identiﬁed within the bile culture at the
time of PD were responsible for subsequent infection in 68% of
patients developing an infective complication. This ﬁgure is in
keeping with the published literature where the organism iso-
lated from bile has been linked to subsequent infection in
50e100% of cases 10,11,2528. In patients not manifesting identical
organisms, the infection may have occurred de-novo following
alteration of microbial ﬂora due to standard cephalosporin and
metronidazole. Interestingly, of 179 patients with bactibilia,
Candida species were identiﬁed in 43 cases and although anti-
bacterial prophylaxis is administered, anti-fungals are not
routinely prescribed. The importance of Candida is variable in the
literature, and whilst some studies report the fungus as a common
ﬁnding, others such as Isla et al., identiﬁed Candida in only 1% of
cultures.27
The insertion of biliary drainage catheters prior to referral is not
unique to this series, and was reported as a major problem by
Cortes et al.28 who noted this to be the case in 79% of cases. One of
the main problems with assessing pre-operative stenting is the lack
of standardisation for stenting, with some interventional endo-
scopists inserting stents for all patients suspected of having
a tumour prior to staging. In such cases imaging with both
computed tomography and endoscopic ultrasound may be
compromised. In addition there is no standard bilirubin level at
which stenting is advocated and most surgeons do not have
a threshold abovewhich they insist on stenting. In an elegant study,
Mansﬁeld et al., examined bilirubin levels at presentation in their
patients with pancreatic and periampullary malignancies and then
followed subsequent increases in bilirubin until relief of jaundice.25
The median bilirubin at presentation in a series of 111 patients was
160 mmol/L. The bilirubin levels increased at a median increase of
13.1 mmol/L per day. It took 3,13, 22 and 31 days respectively for the
bilirubin to reach 200 mmol/L, 300 mmol/L, 400 mmol/L and
500 mmol/L thus indicating a window of opportunity for referral
and surgery without the need for drainage. Thus if a threshold of
300 mmol/L is accepted then the surgeon has 2 weeks to stage and
operate upon the patient.One interesting ﬁnding was the identiﬁcation of a higher
infection rate in patients undergoing ERCP compared with PTC. This
is particularly interesting since most patients now undergoing PTC
do so after failed ERCP, and only a small minority would undergo
primary PTC due to unfavourable anatomy. Furthermore the liter-
ature would suggest that growth seen in undrained and PTC
patients is usually mono-microbial whereas that in patients with
a stent placed at ERCP is usually polymicrobial.29 In this series 64%
of PTC cultures were mono-microbial whereas for the ERCP group
the ﬁgure was only 41%.
A potential criticism of the study is that we did not use the
current deﬁnition of a pancreatic ﬁstulas as suggested by Bassi and
colleagues.30 However, this deﬁnition was accepted by the HPB
community after the commencement of the current study. Prior to
this there were numerous different deﬁnitions in the literature31
and our database was designed with the drain amylase of
>5000 IU/L on day ﬁve as the criteria for meeting the diagnosis of
pancreatic leak.
One area in which selective stenting may be of importance is in
relation to neoadjuvant therapy. As the evidence for such therapy
increases, there may be a need for stenting with metallic stents as
the interval between diagnosis and surgery may be 3e4
months.32,33 There is good data to suggest that metallic stents are
more efﬁcacious than plastic stents34 and do not compromise
subsequent resections.125. Conclusions
Pre-operative stent insertion prior to PD is associated with
increased morbidity which is greatest for stents placed at ERCP.
The risk is present at 30 days and persists at 1 year. Efforts should
be made to refer for consideration of resection prior to stenting of
the biliary tree. Furthermore, bile cultures should be taken
routinely and infections treated appropriately, as biliary infection
is also associated with increased morbidity independent of
stenting.
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